{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:45:33Z","timestamp":1779165933558,"version":"3.51.4"},"reference-count":49,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2019,1,2]]},"DOI":"10.1080\/13696998.2018.1534738","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T16:21:13Z","timestamp":1539188473000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin\u2019s lymphoma: a United States payer perspective"],"prefix":"10.1080","volume":"22","author":[{"given":"Samuel","family":"Large","sequence":"first","affiliation":[{"name":"PAREXEL International, London, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hettle","sequence":"additional","affiliation":[{"name":"PAREXEL International, London, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Balakumaran","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Wu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah H.","family":"Borse","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"CIT0001","unstructured":"American Cancer Society. Lymphoma. Atlanta, Georgia: ACS; 2015; Available at: http:\/\/www.cancer.org\/cancer\/hodgkindisease\/detailedguide\/hodgkin-disease-what-is-hodgkin-disease [Last accessed November 7, 2017]"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4817"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717728000"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.1999.17.10.3101","volume":"17","author":"Sweetenham JW","year":"1999","journal-title":"J Clin Oncol"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.534"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.486090"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu387"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4689"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","volume":"81","author":"Chopra R","year":"1993","journal-title":"Blood"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11414"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"CIT0019","unstructured":"U.S. Food and Drug Administration. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. Washington, D.C.: US FDA; 2017. Available at: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm546893.htm [Last accessed November 24, 2017]"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"CIT0021","unstructured":"U.S. Food and Drug Administration. ADCETRIS: highlights of prescribing information. Washington, D.C.: US FDA; 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125388_S056S078lbl.pdf [Last accessed November 8, 2017]"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw169"},{"key":"CIT0023","unstructured":"National Center for Health Statistics. Life Tables. Hyattsville, MD: NCHS; 2014. Available at: https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm [Last accessed November 7, 2017]"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540150055031"},{"key":"CIT0025","unstructured":"Phillippo DM, Ades AE, Dias S, et\u00a0al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. Sheffield, UK: NICE; 2016. Available at: http:\/\/www.nicedsu.org.uk [Last accessed November 7, 2017]"},{"key":"CIT0026","unstructured":"Merck, KEYNOTE-087 CSR. Kenilworth, NJ; Data on file; 2016"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"CIT0028","unstructured":"National Institute of Health and Care Excellence. Lymphoma (Hodgkin's, CD30-positive) - brentuximab vedotin [ID722]. London, UK: NICE; 2016. Available at: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag467"},{"key":"CIT0029","unstructured":"Merck, Kenilworth, NJ; Data on file. 2016"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"CIT0031","first-page":"2377","volume":"128","author":"Shao C","year":"2016","journal-title":"Utilization patterns and resource use in relapse\/refractory Hodgkin lymphoma (rrHL) patients treated with brentuximab vedotin (BV)"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200503000-00003"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-003-0182-5"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.970542"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180261"},{"key":"CIT0037","unstructured":"National Inpatient Sample 2017, Healthcare Cost and Utilization Project (HCUP). Kenilworth, NJ: Agency for Healthcare Research and Quality; 2017."},{"key":"CIT0038","unstructured":"Merck, US Market Research. Kenilworth, NJ; Data on file. 2017"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.332"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4906-508"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"CIT0043","unstructured":"U.S. Food and Drug Administration. GEMZAR (gemcitabine for injection): Highlights of prescribing information. Washington, D.C.: US FDA; 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020509s077lbl.pdf [Last accessed November 17, 2017]"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"CIT0046","unstructured":"National Institute of Health and Care Excellence. Paclitaxel as albumin-boundnanoparticles with gemcitabine for untreated metastatic pancreatic cancer. London, UK: NICE; 2017. Available at: https:\/\/www.nice.org.uk\/guidance\/ta476\/resources\/paclitaxel-as-albuminbound-nanoparticles-with-gemcitabine-for-untreated-metastatic-pancreatic-cancer-pdf-82604969382085 [Last accessed November 7, 2017]"},{"key":"CIT0047","unstructured":"National Institute of Health and Care Excellence. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin\u2019s B-cell lymphoma. London, UK: NICE; 2014. Available at: https:\/\/www.nice.org.uk\/guidance\/ta306\/resources\/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma-pdf-82602369336517 [Last accessed November 7, 2017]"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9589-5"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2018.1534738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T16:03:13Z","timestamp":1599408193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2018.1534738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,2]]}},"alternative-id":["10.1080\/13696998.2018.1534738"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2018.1534738","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}